Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria

Carla Boschetti, Elisa Fermo, Paola Bianchi, Cristina Vercellati, Fiorenza Barraco, Alberto Zanella

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We reviewed clinical and molecular data of 23 consecutive unrelated patients affected by paroxysmal nocturnal hemoglobinuria (PNH) (19 with hemolytic PNH, 3 with aplastic anemia/PNH, and 1 with myelodysplasia/PNH syndrome) with a mean follow-up of 11.8 years. Five patients had thrombotic episodes, and 10 needed regular blood transfusions; 2 died for cerebral hemorrhage and kidney failure, and 2 spontaneously recovered from PNH. Twenty different PIG-A gene mutations were detected in 21/23 patients: 15 frameshift, 1 splicing, 2 nonsense, and 2 missense mutations. Two mutations (DelG341 and IVS2 + 1g-a) were detected twice. A PIG-A mutated clone was also revealed in the two patients in complete clinical remission. One patient with aplastic anemia/PNH syndrome was treated with two courses of antilymphocyte globulin and cyclosporin with partial sustained response. Six patients were given rHu-EPO 150 U/kg/day sc for at least 6 months: one became transfusion-independent for 8 months and then discontinued treatment for clinical complications; one displayed a mean rise of Hb of 1.5 g/dL and is currently maintaining Hb levels higher than 9 g/dL after 54 months of therapy. Mutation specific quantitative-competitive PCR showed that the rise of hemoglobin was related to an increase of PIG-A negative molecules, suggesting that the efficacy of rHu-EPO therapy may be due to the stimulation of the abnormal clone.

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalAmerican Journal of Hematology
Volume77
Issue number1
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Paroxysmal Hemoglobinuria
Aplastic Anemia
Mutation
Clone Cells
Antilymphocyte Serum
Cerebral Hemorrhage
Missense Mutation
Blood Transfusion
Cyclosporine
Renal Insufficiency
Hemoglobins
Therapeutics
Polymerase Chain Reaction
Genes

Keywords

  • Aplastic anemia
  • Immunosuppression
  • Paroxysmal nocturnal hemoglobinuria
  • PIG-A gene
  • rHu-EPO therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. / Boschetti, Carla; Fermo, Elisa; Bianchi, Paola; Vercellati, Cristina; Barraco, Fiorenza; Zanella, Alberto.

In: American Journal of Hematology, Vol. 77, No. 1, 09.2004, p. 36-44.

Research output: Contribution to journalArticle

@article{83010e16b23d48ec93561df85120b791,
title = "Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria",
abstract = "We reviewed clinical and molecular data of 23 consecutive unrelated patients affected by paroxysmal nocturnal hemoglobinuria (PNH) (19 with hemolytic PNH, 3 with aplastic anemia/PNH, and 1 with myelodysplasia/PNH syndrome) with a mean follow-up of 11.8 years. Five patients had thrombotic episodes, and 10 needed regular blood transfusions; 2 died for cerebral hemorrhage and kidney failure, and 2 spontaneously recovered from PNH. Twenty different PIG-A gene mutations were detected in 21/23 patients: 15 frameshift, 1 splicing, 2 nonsense, and 2 missense mutations. Two mutations (DelG341 and IVS2 + 1g-a) were detected twice. A PIG-A mutated clone was also revealed in the two patients in complete clinical remission. One patient with aplastic anemia/PNH syndrome was treated with two courses of antilymphocyte globulin and cyclosporin with partial sustained response. Six patients were given rHu-EPO 150 U/kg/day sc for at least 6 months: one became transfusion-independent for 8 months and then discontinued treatment for clinical complications; one displayed a mean rise of Hb of 1.5 g/dL and is currently maintaining Hb levels higher than 9 g/dL after 54 months of therapy. Mutation specific quantitative-competitive PCR showed that the rise of hemoglobin was related to an increase of PIG-A negative molecules, suggesting that the efficacy of rHu-EPO therapy may be due to the stimulation of the abnormal clone.",
keywords = "Aplastic anemia, Immunosuppression, Paroxysmal nocturnal hemoglobinuria, PIG-A gene, rHu-EPO therapy",
author = "Carla Boschetti and Elisa Fermo and Paola Bianchi and Cristina Vercellati and Fiorenza Barraco and Alberto Zanella",
year = "2004",
month = "9",
doi = "10.1002/ajh.20144",
language = "English",
volume = "77",
pages = "36--44",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria

AU - Boschetti, Carla

AU - Fermo, Elisa

AU - Bianchi, Paola

AU - Vercellati, Cristina

AU - Barraco, Fiorenza

AU - Zanella, Alberto

PY - 2004/9

Y1 - 2004/9

N2 - We reviewed clinical and molecular data of 23 consecutive unrelated patients affected by paroxysmal nocturnal hemoglobinuria (PNH) (19 with hemolytic PNH, 3 with aplastic anemia/PNH, and 1 with myelodysplasia/PNH syndrome) with a mean follow-up of 11.8 years. Five patients had thrombotic episodes, and 10 needed regular blood transfusions; 2 died for cerebral hemorrhage and kidney failure, and 2 spontaneously recovered from PNH. Twenty different PIG-A gene mutations were detected in 21/23 patients: 15 frameshift, 1 splicing, 2 nonsense, and 2 missense mutations. Two mutations (DelG341 and IVS2 + 1g-a) were detected twice. A PIG-A mutated clone was also revealed in the two patients in complete clinical remission. One patient with aplastic anemia/PNH syndrome was treated with two courses of antilymphocyte globulin and cyclosporin with partial sustained response. Six patients were given rHu-EPO 150 U/kg/day sc for at least 6 months: one became transfusion-independent for 8 months and then discontinued treatment for clinical complications; one displayed a mean rise of Hb of 1.5 g/dL and is currently maintaining Hb levels higher than 9 g/dL after 54 months of therapy. Mutation specific quantitative-competitive PCR showed that the rise of hemoglobin was related to an increase of PIG-A negative molecules, suggesting that the efficacy of rHu-EPO therapy may be due to the stimulation of the abnormal clone.

AB - We reviewed clinical and molecular data of 23 consecutive unrelated patients affected by paroxysmal nocturnal hemoglobinuria (PNH) (19 with hemolytic PNH, 3 with aplastic anemia/PNH, and 1 with myelodysplasia/PNH syndrome) with a mean follow-up of 11.8 years. Five patients had thrombotic episodes, and 10 needed regular blood transfusions; 2 died for cerebral hemorrhage and kidney failure, and 2 spontaneously recovered from PNH. Twenty different PIG-A gene mutations were detected in 21/23 patients: 15 frameshift, 1 splicing, 2 nonsense, and 2 missense mutations. Two mutations (DelG341 and IVS2 + 1g-a) were detected twice. A PIG-A mutated clone was also revealed in the two patients in complete clinical remission. One patient with aplastic anemia/PNH syndrome was treated with two courses of antilymphocyte globulin and cyclosporin with partial sustained response. Six patients were given rHu-EPO 150 U/kg/day sc for at least 6 months: one became transfusion-independent for 8 months and then discontinued treatment for clinical complications; one displayed a mean rise of Hb of 1.5 g/dL and is currently maintaining Hb levels higher than 9 g/dL after 54 months of therapy. Mutation specific quantitative-competitive PCR showed that the rise of hemoglobin was related to an increase of PIG-A negative molecules, suggesting that the efficacy of rHu-EPO therapy may be due to the stimulation of the abnormal clone.

KW - Aplastic anemia

KW - Immunosuppression

KW - Paroxysmal nocturnal hemoglobinuria

KW - PIG-A gene

KW - rHu-EPO therapy

UR - http://www.scopus.com/inward/record.url?scp=4243107303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243107303&partnerID=8YFLogxK

U2 - 10.1002/ajh.20144

DO - 10.1002/ajh.20144

M3 - Article

C2 - 15307104

AN - SCOPUS:4243107303

VL - 77

SP - 36

EP - 44

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -